Statement of Independence
The Infectious Disease & Antimicrobial Research Institute (IDARI) operates as a 501(c)(3) nonprofit organization with no parent company, subsidiary, or controlling financial interest held by a pharmaceutical manufacturer, pharmacy benefit manager, wholesaler, or health insurance entity. Editorial decisions — including topic selection, content framing, and publication of research findings — are made exclusively by IDARI research and editorial staff, independent of any commercial relationship.
This policy governs all individuals who contribute to IDARI publications in any capacity: staff authors, external contributing authors, peer reviewers, editorial advisory board members, and governance committee members.
Disclosure Requirements
All contributors must disclose the following categories of interest prior to contributing to IDARI content, and must update disclosures within 30 days of any material change:
Handling of Disclosed Conflicts
Disclosed interests are evaluated by the Editor-in-Chief and at least one Research Governance Committee member. The following dispositions apply:
| Conflict Type | Disposition |
|---|---|
| Direct employment by affected company | Disqualification from contributing to relevant content |
| Advisory board / consulting (relevant company) | Disqualification from relevant peer review; may author with mandatory disclosure notation |
| Speaking honoraria (relevant company, past 24 mo.) | Mandatory disclosure notation; editorial oversight review |
| Equity ownership (relevant company) | Disqualification from contributing to relevant content |
| Research grant (relevant company, administered) | Mandatory disclosure notation; independent co-author required |
| No relevant commercial relationship | No restriction; disclosure notation confirms absence of conflict |
Current Staff Disclosures
Dr. Richard Vance, PharmD, PhD — Lead Clinical Pharmacologist
Dr. Vance has no current employment, consulting, advisory board, equity, or speaking arrangements with any pharmaceutical manufacturer, pharmacy benefit manager, or telehealth company. He has received no industry-sponsored research funding within the past 36 months. No relevant conflicts to disclose.
Disclosures are updated annually or within 30 days of any material change. This statement last verified: November 2025.
Reporting Potential Violations
Concerns about undisclosed conflicts of interest may be submitted confidentially to [email protected]. IDARI investigates all credible concerns within 30 days and takes corrective action where warranted, up to and including retraction of affected content and termination of the contributor relationship.